The Buda Health Center is one of the leading private institutions of Budapest offering its patients personalized comprehensive health care.

Magyar

Dömötör, Eszter, MD Ph.D.

 

Medical specialism

  • Therapy of anxiety and depression

Professional experience

  • 1994 – 2001: Department of Medical Biochemistry, Semmelweis University
    • 1994 – 1997: Ph.D. student
    • 1997 – 2000: Medical intern
    • 2000 – 2001: Academic assistant
  • 2001 – 2003: Division of Neurovascular Biology, Frank Smith Laboratories for Neurosurgery, University of Rochester
    • Postdoctoral scientific colleague
  • 2003 – 2006: Department of Psychiatry and Psychotherapy, Semmelweis University
    • Internship
  • 2006 – 2007: Kútvölgyi Clinical Block, Semmelweis University
    • Psychiatrist specialist candidate
  • 2007 – 2011: Department of Psychiatry, Szent János Hospital and North Buda United Hospitals
    • Psychiatrist
  • 2008 – : Private practice
  • 2008 – : Buda Health Center
    • Private practice
  • 2011 – 2014: Mental Health Clinic, Medical Non-profit Kft. of Újpest
    • Psychiatrist
  • 2016 – 2017: 1st Department of Psychiatry and Psychiatric Rehabilitation, Jahn Ferenc Hospital of South Pest
    • Head of Department
  • 2014 – 2016, 2017 – : Psychiatric Clinic, Medical Institute of XV. District’s Local Government
    • 2014 – 2016: Head of Department
    • 2017 – : Senior doctor

Education and qualifications

  • 1994: Faculty of Medicine – Semmelweis University
  • 2000: Ph.D., Neuroscience, Semmelweis University
  • 2008: qualifying exam in psychiatry
  • 2010: psychodramatic course
  • 2017: hypnotherapy course

Language skills

  • English

Scientific activity

  • Dömötör E, Hermánné EF. “Comparison of antidepressant effect of agomelatine and escitalopram in major depression: a retrospective investigation at a psychiatric outpatient clinic.” kézirat General Med. 2016.
  • Domotor E, Hermanne EF.” [The temporal accuracy of agomelatine administration and comparison of antidepressant effect of agomelatine and escitalopram in major depression: a retrospective investigation at a psychiatric outpatient clinic]. Az gomelatinszedés pontossága és az agomelatin- escitalopram antidepresszív hatásának összehasonlítása major depresszióban: retrospektív vizsgálat a pszichiátriai szakrendelő betegeinél. Az ördög a részletekben rejlik,” Neuropsychopharmacol Hung. Jun;17(2):59-67. 2015. 
  • Hejjas K, Szekely A, Domotor E, Halmai Z, Balogh G, Schilling B, Sarosi A, Faludi G, Sasvari-Szekely M, Nemoda Z. “Association between depression and the Gln460Arg polymorphism of P2RX7 Gene: A dimensional approach.” American Journal of Medical Genetics B Neuropsychiatr. Genet. 150B(2):295-9 2009.
  • Halmai Z, Dömötör E, Balogh G, Sárosi A, Faludi G, Székely A. “Validation of a new mood questionnaire on a healthy sample.” Neuropsychopharmacol. Hung;10(3):151-7. Hungarian 2008.
  • Sarosi A, Gonda X, Balogh G, Domotor E, Szekely A, Hejjas K, Sasvari-Szekely M, Faludi G. “Association of the STin2 polymorphism of the serotonin transporter gene with a neurocognitive endophenotype in major depressive disorder.” Prog Neuropsychopharmacol Biol Psychiatry. Jul 3, 2008. 
  • Dömötör E, Sárosi A, Balogh G, Székely A, Héjjas K, Sasvári-Székely M, Faludi G.
    “Association of neurocognitive endophenotype and STin2 polymorphism in major depressive disorder” Neuropsychopharmacologia Hungarica (2):53-62. 2007.
  • Hejjas K, Domotor E, Szekely A, Balogh G, Sarosi A, Faludi G, Sasvari-Szekely M. “Case-control study of serotonin transporter polymorphism in major depressive disorders.” American Journal of Medical Genetics B Neuropsychiatr.Genet. 141B (7): 741-741, 2006.
  • Faludi G, Domotor E, Balogh G, Sarosi A, Szekely A, Hejjas K, Sasvari-Szekely M. “Association between the STIN2 but not the 5-HTTLPR polymorphism of the serotonin transporter and major depressive disorder.” Int. J. Neuropsychopharmacology 9: S176-S176 Suppl. 1 2006.
  • Domotor, E., Benzakour, O., Griffin, JH., Fukudome, K. Yule, D. and Zlokovic BV. “Activated Protein C alters cytosolic Ca2+ in human brain endothelium via binding to endothelial protein C receptor and activation of Protease-Activated Receptor-1”. Blood 101(12) 4797-4801, 2003. IF: 10,12
  • Dömötör, E., Bartha, K., Machovich, R. and Adam-Vizi, V. “Protease-activated receptor-2 (PAR-2) in the brain microvascular endothelium and its regulation by plasmin and elastase.” Journal of Neurochemistry 80, 746-754, 2002. IF: 4,97
  • Sipos, I., Dömötör, E., Abbott, NJ. and Adam-Vizi, V. “The pharmacology of nucleotide receptors on primary brain endothelial cells grown on a biological extracellular matrix: effects on intracellular calcium concentration.” British Journal of Pharmacology 131, 1195-1203, 2000. IF: 3,69
  • Bartha, K., Dömötör, E., Lanza, F., Adam-Vizi, V. and Machovich, R. “Identification of thrombin receptors in rat brain capillary endothelial cells.” Journal of Cerebral Blood Flow and Metabolism 20, 175-182, 2000. IF: 5,93
  • Dömötör, E., Abbott, NJ. and Adam-Vizi, V. “Na+-Ca2+ exchange and its implication for calcium homrostasis in primary cultured rat brain microvascular endothelial cells.” Journal of Physiology (London) 515, 147-155, 1999. IF:4,552
  • Dömötör, E., Sipos, I., Kittel, A., Abbott, NJ. and Adam-Vizi, V. “Improved growth of cultured brain microvascular endothelial cells on glass coated with a biological matrix”. Neurochemistry International 33, 473-478, 1998. IF:1,781


Should You like to make an appointment with our collegue for private consultation, please dial the number +36-1-489-5200, where our dispatchers will answer your call between 8am and 8pm every weekday!



Suspension of outpatient and inpatient care in non-acute cases

Dear Visitor,


Amidst the current epidemiological situation and in line with the orders of the competent government bodies, the Buda Health Center (BEK Kft.) is suspending its outpatient and inpatient care in non-acute cases with immediate effect.      

We will continuously keep our contractual partners posted about how the logistics of the services evolve through the competent experts and those responsible for organising our healthcare provision.      

As far as ongoing treatments are concerned, our dispatchers will continuously keep patients posted following the guidance of their respective doctors. Should you have any questions, we recommend contacting your doctor via email through the institute’s email address.      

This measure will change based on central orders upon the alleviation of the epidemic.      


Sincerely,


Péter Pál Varga, M.D.
General Director